U.S. Hospitality Stock News

In May 2026, ICU Medical’s Vice President and General Counsel, Virginia Ruth Sanzone, sold 2,447 shares, about 11.17% of her direct holdings, while the Smiths Medical integration neared completion with manufacturing consolidation largely finished and new pump lines in development. At the same time, Madison Small Cap Fund disclosed a new position in ICU Medical, highlighting the company’s infusion therapy focus, market share gains amid competitors’ quality issues, and a high-volume connected...

Macy's stock performance and recent context Macy's (M) stock has recently attracted attention after a strong stretch of returns, including gains over the past week, month, and past 3 months. This performance has prompted investors to reassess the department store retailer's valuation and fundamentals. See our latest analysis for Macy's. At a share price of $25.37, Macy's recent momentum is strong, with a 30 day share price return of 37.81% and a 1 year total shareholder return of 132.50%...

Dollar Tree recently reported past Q1 2026 results showing net sales growth, higher comparable-store sales, a large adjusted EPS increase, and nearly US$600 million in share repurchases, alongside raising its full-year adjusted EPS guidance. Beneath the strong headline figures, Dollar Tree’s expanding multiprice assortment and growing appeal to higher-income beauty shoppers highlight a meaningful shift in its customer mix and profit drivers. We’ll now examine how Dollar Tree’s upgraded...

Earlier this month, Diehl Defence announced it had signed a Memorandum of Understanding with Spire Global at the ILA Berlin Airshow 2026 to explore collaboration on satellite-based intelligence and early warning against ballistic and hypersonic missiles, drawing on Spire’s RF detection and analytics capabilities. This collaboration framework, paired with Spire’s new Munich facility capable of producing up to 100 satellites per year, highlights how the company is positioning itself as a...

Earlier this month, MiniMed announced an expanded agreement with Abbott to commercialize Abbott’s CE‑marked dual glucose–ketone Libre Duo sensors in Europe, while Abbott’s board approved its 410th consecutive quarterly dividend of US$0.63 per share payable on August 17, 2026. This combination of long-running dividend continuity and first-of-its-kind dual-analyte diabetes technology underscores how Abbott is pairing cash returns with ongoing innovation in chronic disease management. We’ll now...

In recent weeks, Roper Technologies has drawn fresh attention from institutional investors and analysts, who highlighted its resilient portfolio of vertical software and technology‑enabled businesses, robust free cash flow, and shareholder‑friendly policies such as double‑digit dividend growth and active share repurchases. At the same time, ongoing strength in its Technology Enabled Products segment and enhancements like DAT Freight & Analytics’ expanded reloads feature are reinforcing the...

Conference spotlight puts CBIZ in focus CBIZ (CBZ) is back in the spotlight after presenting at the 46th Annual William Blair Growth Stock Conference in Chicago, drawing attention to a stock that has been rebounding from long term lows. Recent coverage links the move in CBIZ shares to improving technical signals, a wide gap to some valuation estimates, and insider buying, while still flagging risks around AI disruption concerns and acquisition related leverage. See our latest analysis for...

Insperity (NSP) has been in focus after its latest quarterly update, where Q1 revenue of US$1.90b aligned with expectations but full year EPS guidance fell short, prompting a 2.4% share price decline. See our latest analysis for Insperity. Beyond the immediate reaction to earnings, Insperity’s share price has climbed 21.07% over the past 30 days and 68.51% over 90 days, while the 1 year total shareholder return is down 34.90%. This suggests that recent momentum contrasts with a weaker longer...

Packaging Corporation of America recently presented at the 16th Annual Wells Fargo Industrials & Materials Conference and later indicated it may miss second-quarter earnings guidance due to higher freight and recycled fiber costs and weaker outside sales. Despite this guidance concern and recent insider share sales of about US$2.0 million, several analysts have reiterated positive ratings, highlighting confidence in the company’s longer-term demand drivers and acquisition benefits. We’ll now...

Earlier in June 2026, Neurocrine Biosciences reported new post-hoc KINECT 4 trial data and clinician-reported real-world findings showing that INGREZZA (valbenazine) produced clinically meaningful reductions in tardive dyskinesia movements and functional gains across varied adult patient groups, including those with intellectual and developmental disabilities. Together, these results highlight INGREZZA’s breadth of evidence in complex, often underserved populations and underscore its...

Earlier this month at the American Diabetes Association’s Scientific Sessions in New Orleans, DexCom reported CONNECT trial results showing its G7 continuous glucose monitor significantly lowered A1C and improved glucose control in adults with Type 2 diabetes not using insulin compared with traditional finger-stick testing. The breadth of benefit across demographics and medication regimens suggests DexCom’s CGM technology could be relevant to a much wider Type 2 population than historically...

In June 2026, Xometry, Inc. completed a US$225.00 million follow-on offering of 2,647,059 Class A shares at US$85.00 each, alongside filing a US$225.00 million follow-on and an omnibus shelf registration covering common stock, preferred stock, debt securities, and warrants. By securing fresh equity capital and a broad shelf registration, Xometry has expanded its funding toolbox, potentially supporting future technology investment, marketplace expansion, and balance sheet flexibility. Next,...

In recent days, Twist Bioscience expanded its antibody discovery capabilities through a bispecific antibody licensing agreement with Invenra and released new next-generation sequencing library preparation kits aimed at supporting clinical research. These moves, combined with analyst coverage highlighting Twist’s role in AI-enabled drug discovery and life sciences tools, have sharpened investor focus on how the company might balance growth ambitions with ongoing losses and insider share...

Earlier this month, StandardAero announced that long-time CEO Russell Ford will retire after 13 years, with current Lead Independent Director Paul McElhinney, a 35-year aerospace veteran, set to assume the CEO role on October 1, 2026. Ford, who oversaw StandardAero’s transformation into a more than US$6.00 billion-revenue public company, will stay on as Executive Chairman through 2026 while McElhinney brings prior GE Aviation and GE Power Services leadership experience to guide the company’s...

Recently, analysis of Enova International highlighted that its incremental sales growth has been less profitable, with earnings lagging revenue and a high net‑debt‑to‑EBITDA ratio suggesting elevated balance sheet strain. This combination of weaker profit conversion and heavy leverage has intensified questions about financial sustainability and the potential for shareholder dilution at Enova. Next, we’ll examine how concerns over Enova’s high net‑debt‑to‑EBITDA ratio reshape its investment...

Recent sentiment on M/I Homes (MHO) has turned cautious, with expectations for a year over year EPS decline even as quarterly revenue is projected higher. This is putting extra attention on the upcoming earnings webcast. See our latest analysis for M/I Homes. The recent caution around earnings comes after a strong run, with a 16.48% 1 month share price return and a 32.06% 1 year total shareholder return suggesting momentum has been building despite near term concerns. If this kind of move has...

Earlier this week, Oracle reported record fiscal 2026 results, including US$19.18 billion in fourth-quarter revenue and US$17.09 billion in annual net income, while confirming guidance for US$90 billion in fiscal 2027 revenue and announcing plans to raise about US$40 billion in new debt and equity to fund AI data center expansion. Award of a US$395.8 million, 10-year federal HR platform contract and large AI-driven cloud wins highlight how Oracle is tying long-duration government and...

Recent commentary around Somnigroup International (SGI) has focused on muted revenue growth and declining returns on capital, raising fresh questions about whether recent investments are adding or eroding value for shareholders. See our latest analysis for Somnigroup International. After a weak start to the year, with the share price down 18.58% year to date and 6.29% over 90 days, a 15.27% 1 month share price return and 6.23% 7 day gain suggest some short term momentum. At the same time, the...

Rexford Industrial Realty (REXR) is back in focus after better than expected first quarter 2026 results and shareholder backing for all annual meeting proposals, even as Southern California demand concerns remain part of the story. See our latest analysis for Rexford Industrial Realty. At a share price of $35.09, Rexford Industrial Realty has seen short term momentum pick up, with a 7 day share price return of 2.99%. This comes even as the year to date share price return is down 10.09% and...

Tronox Holdings has released its 2025 sustainability report, confirming it exceeded its environmental and safety targets and permanently closed its Fuzhou TiO₂ plant in China to better align operations with market conditions. The report links these environmental gains and footprint changes with progress in Tronox’s rare earths program, underscoring how sustainability efforts are being tied directly to future product and market opportunities. Next, we’ll examine how Tronox’s progress in rare...

Phase 2 PWS data and what it could mean for Rhythm Pharmaceuticals stock Rhythm Pharmaceuticals (RYTM) recently reported six month interim Phase 2 data for setmelanotide in Prader Willi syndrome, highlighting clinically meaningful changes in BMI, fat mass, hyperphagia, and anxiety, and outlined plans to move into Phase 3 development. See our latest analysis for Rhythm Pharmaceuticals. The latest PWS data arrives after a mixed share price stretch, with the stock down 15.84% year to date on a...

New Australian Leadership Adds Context to Everest Group’s Recent Momentum Everest Group (EG) has appointed Peter Chalkias as country head and chief financial officer for Australia, adding fresh leadership in a market where the insurer is already emphasizing reinsurance, capital efficiency and international growth. See our latest analysis for Everest Group. The latest executive move in Australia comes as Everest Group’s share price shows a 5.89% 90 day share price return and a 60.15% five year...

The Coca-Cola Company announced in June 2026 that it is exploring a public listing in India of Hindustan Coca-Cola Holdings, parent of its largest Indian bottler, around 2027, potentially selling part of its stake on the Bombay Stock Exchange and National Stock Exchange of India. This prospective listing, following the Jubilant Bhartia Group’s 40% acquisition of Hindustan Coca-Cola Holdings in 2025, would mark a key step in Coca-Cola’s refranchising push and could reshape how it taps the...

Earlier this month, Goldman Sachs upgraded New Oriental Education & Technology Group from Neutral to Buy, highlighting the company’s approximately US$5.40 billion net cash position and expectations for margin expansion in test preparation and livestreaming businesses. This reassessment by a major global bank underscores how New Oriental’s substantial cash reserves and improving profitability profile may be reshaping perceptions of its financial resilience. Next, we’ll examine how Goldman...